Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optos introduces new retinal scanning device

This article was originally published in Clinica

Executive Summary

Eye imaging firm Optos is launching a new ultra-wide field retinal imaging device, 200Tx, worldwide. The product is the first to incorporate auto-fluorescence technology to help detect changes in the retinal pigment epithelium, a pigmented cell layer just outside the retina. This could aid the diagnosis and management of age-related macular degeneration (AMD). Previously, the disorder was not thought to affect peripheral vision, but a study using 200Tx reported in September that 76% of eyes in 122 AMD patients had peripheral abnormalities, and that adding auto-fluorescence improved the detection of AMD (www.clinica.co.uk, 3 September 2010). Dunfermline, UK-based Optos exhibited the new device at the annual meeting of the American Academy of Ophthalmology, being held in Chicago, Illinois on 16-19 October, and plans to launch it commercially in the first quarter of 2011.

Topics

UsernamePublicRestriction

Register

MT095860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel